About

Overview

Catalyst is a biopharmaceutical company focused on protease therapeutics to address unmet medical needs in disorders of the coagulation systems. Catalyst’s product candidates consist of the coagulation related assets marzeptacog alfa (activated) (“MarzAA”), dalcinonacog alfa (“DalcA”), and CB 2679d-GT. MarzAA is a SQ administered next generation engineered coagulation Factor VIIa (“FVIIa”) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. DalcA is a next-generation SQ administered FIX. CB 2679d-GT is an AAV-based gene therapy construct harboring the DalcA sequence. Both MarzAA and DalcA have shown sustained efficacy and safety in mid-stage clinical trials and are available for partnering. CB 2679d-GT has obtained preclinical proof-of-concept and is also available for partnering.

Management Team

We have assembled an experienced leadership team including world-class scientists, advisors, and collaborators. We have established, and continue to expand, a robust intellectual property position to advance and protect our business objectives.

Nassim Usman, Ph.D.

President and Chief Executive Officer

Grant Blouse, Ph.D.

Chief Scientific Officer

Tom Knudsen, DVM, Ph.D.

Senior Vice President, Corporate Development

Seline Miller, CPA

Senior Vice President, Finance

Interim Chief Financial Officer & Interim Principal Accounting Officer

Board

We have assembled an experienced leadership team including world-class scientists, advisors, and collaborators. We have established, and continue to expand, a robust intellectual property position to advance and protect our business objectives.